Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 52Neoplasms 44Prostatic Neoplasms 43Breast Neoplasms 38Neoplasm Metastasis 21Unspecified Adult Solid Tumor, Protocol Specific 19Lung Neoplasms 18Head and Neck Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Ovarian Neoplasms 15Advanced Solid Tumors 11Stomach Neoplasms 9Sarcoma 9Pancreatic Neoplasms 9Solid Tumor 8Melanoma 8Esophageal Neoplasms 8Carcinoma, Ovarian Epithelial 8Urinary Bladder Neoplasms 7Fallopian Tube Neoplasms 7Colorectal Neoplasms 7Small Cell Lung Carcinoma 6Salivary Gland Neoplasms 6Esthesioneuroblastoma, Olfactory 5Esophageal Squamous Cell Carcinoma 5Carcinoma, Renal Cell 5Breast Neoplasms, Male 5Triple Negative Breast Neoplasms 4Recurrence 4Endometrial Neoplasms 4

Interventions

Granisetron 5casopitant 2Cyclophosphamide 2fosaprepitant 1Tablets 1Methadone 1Injections, Intravenous 1Dronabinol 1Docetaxel 1Cannabidiol 1Aprepitant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Vomiting × Docetaxel × Clear all
NCT00440128 2017-08-04

The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer

GlaxoSmithKline

Phase 1 Completed
12 enrolled

Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡